Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Capital Wealth Planning LLC

Capital Wealth Planning LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 246,601 shares of the company’s stock after buying an additional 20,016 shares during the period. Capital Wealth Planning LLC’s holdings in Teva Pharmaceutical Industries were worth $5,435,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TEVA. Smithfield Trust Co boosted its stake in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $60,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $66,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 273.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after purchasing an additional 3,323 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on TEVA shares. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Trading Up 0.8 %

TEVA opened at $16.45 on Friday. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a market cap of $18.64 billion, a P/E ratio of -11.34, a PEG ratio of 1.44 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business’s 50-day simple moving average is $19.54 and its 200-day simple moving average is $18.46.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.